MX2020003049A - Semaglutida en la terapia medica. - Google Patents

Semaglutida en la terapia medica.

Info

Publication number
MX2020003049A
MX2020003049A MX2020003049A MX2020003049A MX2020003049A MX 2020003049 A MX2020003049 A MX 2020003049A MX 2020003049 A MX2020003049 A MX 2020003049A MX 2020003049 A MX2020003049 A MX 2020003049A MX 2020003049 A MX2020003049 A MX 2020003049A
Authority
MX
Mexico
Prior art keywords
semaglutide
medical therapy
therapy
medical
relates
Prior art date
Application number
MX2020003049A
Other languages
English (en)
Inventor
Maria Kabisch
Thomas Hansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60083831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020003049(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2020003049A publication Critical patent/MX2020003049A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a la semaglutida para su uso en el control del peso.
MX2020003049A 2017-10-12 2018-10-10 Semaglutida en la terapia medica. MX2020003049A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17196254 2017-10-12
PCT/EP2018/077654 WO2019072941A1 (en) 2017-10-12 2018-10-10 SEMAGLUTIDE IN MEDICAL THERAPY

Publications (1)

Publication Number Publication Date
MX2020003049A true MX2020003049A (es) 2020-07-27

Family

ID=60083831

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020003049A MX2020003049A (es) 2017-10-12 2018-10-10 Semaglutida en la terapia medica.
MX2025002188A MX2025002188A (es) 2017-10-12 2020-03-19 Semaglutida en la terapia medica
MX2025002189A MX2025002189A (es) 2017-10-12 2020-03-19 Semaglutida en la terapia medica

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2025002188A MX2025002188A (es) 2017-10-12 2020-03-19 Semaglutida en la terapia medica
MX2025002189A MX2025002189A (es) 2017-10-12 2020-03-19 Semaglutida en la terapia medica

Country Status (18)

Country Link
US (4) US12029779B2 (es)
EP (1) EP3694538A1 (es)
JP (2) JP7148605B2 (es)
KR (1) KR20200069316A (es)
CN (4) CN120241968A (es)
AU (2) AU2018348929B2 (es)
BR (1) BR112020006246A2 (es)
CA (1) CA3078652A1 (es)
CL (1) CL2020000812A1 (es)
IL (3) IL322969A (es)
MA (1) MA50358A (es)
MX (3) MX2020003049A (es)
MY (1) MY204827A (es)
PH (1) PH12020550185A1 (es)
SG (1) SG11202002841PA (es)
TW (1) TWI842681B (es)
WO (1) WO2019072941A1 (es)
ZA (3) ZA202503388B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322969A (en) * 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical therapy
WO2021162532A2 (ko) 2020-02-14 2021-08-19 주식회사 지투지바이오 Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물
PE20221575A1 (es) * 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
EP4313016A4 (en) * 2021-03-29 2025-01-22 Sanford Health METHODS AND COMPOSITIONS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES
EP4536691A1 (en) * 2022-06-08 2025-04-16 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
WO2024249659A2 (en) * 2023-05-30 2024-12-05 The Medical College Of Wisconsin, Inc. Methods for weight loss and/or reducing weight gain
WO2024252134A1 (en) * 2023-06-05 2024-12-12 Closed Loop Medicine Ltd Dosing of incretin pathway drugs

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
PT1687019T (pt) 2003-11-20 2018-02-26 Novo Nordisk As Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
EP2494983B1 (en) 2004-11-12 2019-04-24 Novo Nordisk A/S Stable formulations of glp-1
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
AU2006290227B2 (en) 2005-09-14 2012-08-02 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
WO2007121411A2 (en) 2006-04-14 2007-10-25 Mannkind Corporation Glucagon-like peptide 1(glp-1) pharmaceutical formulations
CN101631548B (zh) 2007-01-31 2014-08-27 比艾尔-坡特拉有限公司 Comt抑制剂的单次药物剂量单元和药物组合物
US20100047762A1 (en) 2007-03-20 2010-02-25 Nippon Kayaku Kabushiki Kaisha Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
DK2373681T3 (en) 2008-12-10 2017-04-24 Glaxosmithkline Llc PHARMACEUTICAL COMPOSITIONS OF ALBIGLUTID
NZ619520A (en) 2009-02-13 2015-06-26 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
CA2784757A1 (en) 2009-12-16 2011-07-07 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
CA2822617A1 (en) 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
WO2012177929A2 (en) 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
JP6280501B2 (ja) 2011-09-08 2018-02-14 メレオ バイオファーマ ２ リミテッド 性腺機能低下症および関連疾患の処置ためのアロマターゼ阻害剤の使用
EP2846823B1 (en) 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
CA3067012C (en) 2012-06-29 2021-10-05 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
RS67258B1 (sr) 2012-07-01 2025-10-31 Novo Nordisk As Upotreba dugodelujućih glp-1 peptida
KR20210086717A (ko) * 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
CR20180378A (es) 2015-12-23 2018-12-06 Amgen Inc Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
US10813918B2 (en) 2017-08-04 2020-10-27 Ovid Therapeutics Inc. Use of Gaboxadol in the treatment of diabetes and related conditions
IL322969A (en) 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical therapy

Also Published As

Publication number Publication date
CN111212657A (zh) 2020-05-29
US12029779B2 (en) 2024-07-09
SG11202002841PA (en) 2020-04-29
MX2025002189A (es) 2025-04-02
US20240415935A1 (en) 2024-12-19
CN120241968A (zh) 2025-07-04
AU2018348929B2 (en) 2025-02-27
US20250235511A1 (en) 2025-07-24
JP7475398B2 (ja) 2024-04-26
BR112020006246A2 (pt) 2021-03-30
US12551536B2 (en) 2026-02-17
JP2020536854A (ja) 2020-12-17
MX2025002188A (es) 2025-04-02
WO2019072941A1 (en) 2019-04-18
EP3694538A1 (en) 2020-08-19
CA3078652A1 (en) 2019-04-18
US20240316159A1 (en) 2024-09-26
CN119838000A (zh) 2025-04-18
RU2020114960A (ru) 2021-10-28
KR20200069316A (ko) 2020-06-16
ZA202503388B (en) 2025-09-25
ZA202503350B (en) 2025-09-25
US12295988B2 (en) 2025-05-13
IL322969A (en) 2025-10-01
AU2025203535A1 (en) 2025-06-05
CL2020000812A1 (es) 2020-08-14
CN119950682A (zh) 2025-05-09
IL322968A (en) 2025-10-01
PH12020550185A1 (en) 2021-03-01
IL273470A (en) 2020-05-31
RU2020114960A3 (es) 2022-02-11
ZA202503387B (en) 2025-09-25
AU2018348929A1 (en) 2020-05-07
MA50358A (fr) 2020-08-19
MY204827A (en) 2024-09-18
TW201914611A (zh) 2019-04-16
TWI842681B (zh) 2024-05-21
US20200237876A1 (en) 2020-07-30
JP7148605B2 (ja) 2022-10-05
JP2022132414A (ja) 2022-09-08

Similar Documents

Publication Publication Date Title
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
ZA202503350B (en) Semaglutide in medical therapy
MX378273B (es) Compuestos activos hacia bromodominios.
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
PH12016502167A1 (en) Hdl theraphy markers
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
MX2021014242A (es) Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora.
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
MX2017002489A (es) Agentes terapeuticos humanos.
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
TWD190452S (zh) 口腔保健器具
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
LT3609486T (lt) Sarpogrelatas, skirtas naudoti žinduolių širdies ligų gydymo būdui
EP3342406A4 (en) USE OF DIHYDROXYACETONE IN THE MANUFACTURE OF ANTI-TUMOR MEDICAMENT
EA201690709A1 (ru) Применение одипарцила в лечении мукополисахаридоза
AR095890A1 (es) Uso de ácido trifluoroacético y sales del mismo para tratar la hipercolesterolemia
EA201991866A1 (ru) Комбинированная терапия
EA201692164A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
FR3024718B1 (fr) Plateau rotatif de repas combine s'etendant infiniment
UA89076U (uk) Застосування стоматологічної настойки "касдент" для лікування запальних захворювань ротової порожнини